Medical Treatment of Insulinoma

References

• Stefanini P, Carboni M, Patrassi N. Surgical treatment and prognosis of insulinoma. Clinics in Gastroenterology. 1974; 3: 697.
   Google Scholar
• Williams RH. Textbook of endocrinology. 4th Edition. Philadelphia: Saunders Company, 1974: 940.
   Google Scholar
• Shatney CH, Grage IB. Diagnostic and surgical aspects of insulinoma. A review of 27 cases. Amer J Surg. 1974; 127: 174–84.
   Google Scholar
• Lopez N, Basabe J, Grant A et al. AO 44: an improved hyperglycemic agent. Metabolism. 1971; 20: 373.
   Google Scholar
• Melmon KL, Morelli HF. Clinical pharmacology. Basic principles, second edition. New York: MacMillan Publishing Co., 1978: 198, 542, 816.
   Google Scholar
• Sellers EM, Koch-Weser J. Protein binding and vascular activity of diazoxide. N Engl J Med. 1969; 281: 1141–5.
   Google Scholar
• Pruitt AW, Dayton PG, Patterson JH. Disposition of diazoxide in children. Clin Pharmacol Ther. 1972; 14: 73–82.
   Google Scholar
• Gotz M, Rose.nmayr F. Diazoxidebehandlung idiopatischer Hypoglykamie beim Kind. Wien Klin Wschr. 1972; 84: 356.
   Google Scholar
• Frerichs H, Track NS. Pharmacotherapy of hormone secreting tumors. Clinics in Gastroenterology. 1974; 33: 721.
   Google Scholar
• Milner RDG, Chouksey SK. Effects of fetal exposure to diazoxide in man. Arch Dis Child. 1972; 47: 537–43.
   Google Scholar
• Barjon P, Fourcade J, Monnier L, Mimran A, Taib J. Coma hyperglycemique sans cetoacidose chez deux sujets hypertendus traites par diazoxide intra-veineux. Sem Hop Paris. 1973; 49: 581
   Google Scholar
• Burr IM, Marlisse EB, Stauffacher W, Renold AH. Diazoxide effects on biphasic insulin release: « Adrenergic » suppression and enhancement in the perfused rat pancreas. J Clin Invest. 1971; 50: 1444–50.
   Google Scholar
• Frerichs H, Creutzfeldt W. L’action du diazoxide sur la secretion d’insuline. Medecine et Hygiene. 1968; 969.
   Google Scholar
• Goodman LS, Gilman A. In: The pharmacological basis of therapeutics. 5th Edition. New York: McMillan Publishing Co, 1975: 713, 151 1, 1529.
   Google Scholar
• Schein PS, Delillis RA; Kahn CR, Gordon P, Kraft A, Islet-cell tumors-: current concepts and management. Ann Intern Med. 1973; 79: 239–57.
   Google Scholar
• Today’s drugs: Diazoxide. Brit Med J. 1972; 4: 417–8.
   Google Scholar
• Hunt PS. Differential diagnosis and management of hypoglycemia. Surg Gyn & Obstet. 1967; 371.
   Google Scholar
• L’Hirondel J, Guihard J, Laniece M, Lambertz J, Signoret C, Coquerel G. Hypoglycemics idiopathiques. Ouest Med. 1972; 25: 1947.
   Google Scholar
• Charles MA, Danforth E. Nonketotic hyperglycemia and coma during intravenous diazoxide therapy inuremia. Diabetes. 1971; 20: 501.
   Google Scholar
• Fajans SS, Floyd JC. Diagnosis and medical management of insulinomas. Ann Rev. Med. 1979; 30: 313–29.
   Google Scholar
• Girdwood RH. Blood disorders due to drugs and other agents. Amsterdam: Exerpta Medica; 1973: 190.
   Google Scholar
• Wales JK, Wolff F. Haematological sideeffects of diazoxide. Lancet, i. 1967, 53.
   Google Scholar
• Rubens R, Carlier A, Thiery M, Vermeulen A. Pregnancy complicated by insulinoma. Brit J Obst Gynecol. 1977; 84: 543–7.
   Google Scholar
• Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with Streptozotocin in 52 patients. Ann Intern Med. 1973; 79: 108–18.
   Google Scholar
• Carter SK, Broder L, Friedman M. Streptozotocin and metastatic insulinoma. Ann Intern Med. 1971; 74: 445–6.
   Google Scholar
• de Gennes JL, Mercadier M, Bercovici JP, Rosselin G, Truffert J, Decourt J. Controle therapeutique prolonge par le diazoxide d’une hypoglycemia organique par adeno-carcinome Langerhansien avec metastases hepatiques. Ann Endocr. 1970; 31: 637.
   Google Scholar
• Vavra JJ, Deboer C, Dietz A. et al. Streptozotocin a new anti-bacterial antibiotic. Antibiot Annu. 1959; 7: 230.
   Google Scholar
• Streptozotocin for islet-cell carcinoma. Lancet. 1973; ii: 1063–4.
   Google Scholar
• Handelsman H, Broder LE, Slavik M, Carter SK. Streptozotocin (NSC-85998). Clinical Brochure, National Cancer Institute; 1974.
   Google Scholar
• Carter SK, Broder LE. The cytostatic therapy of hormone secreting tumours of the G1 tract. Clinics in Gastroenterology. 1974; 3: 733.
   Google Scholar
• Schein PS, Kahn R, Gorden P, Wells S, DeVita VT. Streptozotocin for malignant insulinomas ans carcinoid tumors. Arch Intern Med. 1973; 132: 555–61.
   Google Scholar
• Howell SL, Whitfield M. Ultrastructural studies of the destruction of guinea pig pancreatic B cells after injection of Streptozotocin. Horm Metab Res. 1972; 4: 349–54.
   Google Scholar
• Murray-Lyon IM, Eddleston ALWF, Williams SR et al. Treatment of multiple hormoneproducing malignant islet-cell tumor with Streptozotocin. Lancet. 1968; ii: 895–8.
   Google Scholar
• Arnould Y, Ooms HA, Bastenie PA. Treatment of insulinoma with Streptozotocin. Lancet. 1969; 1: 1210–1.
   Google Scholar
• DeWys WD, Stoll R, Au WY, Salisnjak MM. Effects of Streptozotocin on an islet cell carcinoma with hypercalcemia. Am J Med. 1973; 55: 671–6.
   Google Scholar
• Murray-Lyon IM, Cassar J, Coulson R et al. Further studies on Streptozotocin therapy for a multiple hormone producing islet cell carcinoma. Gut. 1971; 12: 717–20.
   Google Scholar
• Nieschlag E, Wombacher H, Kroeger RJ, Habighorst LV. Therapie eines metastasierenden Inselzelltumors mit Streptozotocin. Acta Endocrinol. 1971; 67; 405–16.
   Google Scholar
• Piroska E, Kollin E. Streptozotocin for insulinoma. Ann Intern Med. 1971; 75: 477.
   Google Scholar
• Sadoff L. Effects of Streptozotocin in a patient with islet-cell carcinoma. Diabetes. 1969; 18: 675.
   Google Scholar
• Schreibman PH, De Koliren LG, Arky RA. Metastatic insulinoma treated with Streptozotocin. Ann Intern Med. 1971; 74: 399–403.
   Google Scholar
• Smith CK, Stoll RW, Vance J, Ricketts H, Williams RH. Treatment of malignant insulinoma with Streptozotocin. Diabetologia. 1971; 7: 118.
   Google Scholar
• Stanley NN, Marks V, Kreel L, Mclntyre N. Streptozotocin treatment of malignant islet cell tumor. Brit Med J. 1970; 3: 562–3.
   Google Scholar
• Walter RM, Ensinck JW, Ricketts H, Kendall JW, Williams RH. Insulin and ACTH production by a Streptozotocin responsive islet cell carcinoma. Am J med. 1973; 55: 667–70.
   Google Scholar
• Beylot J, Veyret V, Vallat I, Longy M, Moretti G. Streptozotocine et insulinomes malins. Sent Hop Paris. 1976; 52: 489–96.
   Google Scholar
• Waryter J, Philippides D, Gillet B, Weryha A, Meknini B. Insulinome complique d’une metastase cerebrale recidivante. Ann Med Intern. 1973; 124: 729–34.
   Google Scholar
• Holland JF, Frei E. III. Cancer Medicine. Philadelphia: Lea and Figiger, 1973: 1573.
   Google Scholar
• Sadoff L. Nephrotoxicity of Streptozotocin (NSC-85998). Cancer Chemother Rep. 1970; 54: 457.
   Google Scholar
• Herr RR, Eble TE, Borsy ME, Jahnke HK. Isolation and characterization of Streptozotocin. Antibiot Annu. 1959; 236.
   Google Scholar
• Myerowitz RL, Sartiano GP, Cavallo T. Nephrotoxic and cytoproliferative effects of Streptozotocin. Cancer. 1976; 38: 1550–5.
   Google Scholar
• Cryer PE, Hill GJ. Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia. Cancer. 1976; 38: 2217.
   Google Scholar
• Taylor III SG, Schwartz TB, Zannini JJ, Ryan WG. Streptozotocin therapy for metastatic insulinoma. A rch Intern Med. 1970; 126: 6547.
   Google Scholar
• Arison RN, Feudale EL. Induction of renal tumor by Streptozotocin in rats. Nature. 1967; 214: 1254–5.
   Google Scholar
• Rakieten N, Gordon BS, Cooney DA, Davis RD, Schein PS. Renal tumorigenic action of Streptozotocin (NSC 85998) in rats. Cancer Chemother Rep. 1968; 52: 563.
   Google Scholar
• Berman LD, Hayes J, Sibay T. The oncogenicity of the drug Streptozotocin in the Chinese hamster. Proc Amer /Iss Cancer Res. 1971; 12: 86.
   Google Scholar
• Loftus L, Cuppage FE, Hoogstraten B. Clinical and pathological effects of Streptozotocin. J Lab clin Med. 1974; 84: 407–13.
   Google Scholar
• Sadoff L. Patterns of intravenous glucose tolerance and insulin response before and after treatment with Streptozotocin (NSC 85998). Cancer Chemother Rep. 1972; 56: 61.
   Google Scholar
• Mintz DH, Chez RA, Hutchinson DL. Subhuman primate pregnancy complicated by Streptozotocin induced diabetes mellitus. J Clin Invest. 1972; 51: 837–47.
   Google Scholar
• Blum RH, Carter SK. Adriamycin, a new anticancer drug with significant clinical activity. Ann Intern Med. 1974; 80: 249–59.
   Google Scholar
• Eastman RC, Come SE, Strewler GJ, Gordon P, Kahn CR. Adriamycin therapy for advanced insulinoma. J Clin Endocrinol Metab. 1977; 44: 142–8.
   Google Scholar
• Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treatment Rep. 1979; 63: 827–34.
   Google Scholar
• Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 7107.
   Google Scholar
• O’Bryan RM, Luce JK, Talley RW, Gottlieb JA, Bakder LH, Bonadonna G. Phase II Evaluation of adriamycin in human neoplasia. Cancer. 1973; 32: 1–8.
   Google Scholar
• Alexander J, Dainiak N, Berger HJ et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979; 300: 278 83.
   Google Scholar
• Bristow MR, Mason IW, Billigham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med. 1978; 88: 168–75.
   Google Scholar
• Kushner JP, Hansen VL, Hammar SP. Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin D and mithramycin. Cancer. 1975; 36: 1577–84.
   Google Scholar
• Levin SR, Booker J, Smith DF, Grodsky GM. Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. J Clin Endocrinol Metab. 1970; 30: 400–1.
   Google Scholar
• Jacobs EM, Luce JK, Wood DA. Treatment of cancer with weekly 5-F U. Cancer. 1968; 22: 1233–8.
   Google Scholar
• Livingston RB, Carter SK. Single agents in cancer chemotherapy. New York: IFI/Plenum; 1970: 197.
   Google Scholar
• Longmire WP, Brown J, Buckberg GD. Islet cell tumors of the pancreas. Ann Intern Med. 1968; 68; 203–21.
   Google Scholar
• Moertel, CG, Hanley JA, Johnson LA. Streptozotocin alone compared with Streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189–94.
   Google Scholar
• Kiang DT, Frenning DH, Bauer GE. Mithramycin for hypoglycemia in malignant insulinoma. N Engl J Med. 1978; 299: 134–5.
   Google Scholar
• Kizer JS, Vargas-Cordon M, Brendel L, Bressler R. The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest. 1970; 49: 1942–8.
   Google Scholar
• Levin SR, Grodsky GM, Hagura R. Comparison of the inhibitory effects of diphenyl hydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas. Diabetes. 1972; 21: 856.
   Google Scholar
• Gailani S, Nussbaum A, Ohnuma T. Diabetes in patients treated with asparaginase. Clin Pharmacol Ther. 1971; 12: 487.
   Google Scholar
• Schein PS. Chemotherapeutic management of the hormone secreting endocrine malignancies. Cancer. 1972; 30: 1616–26.
   Google Scholar
• Bisel HF. Ansfield FJ, Mason JH. Clinical studies with tubercidin administered by direct injection. Cancer Res. 1970; 30: 76–8.
   Google Scholar